Replimune Group Stock News

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im

Parametric Portfolio Associates LLC lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 16.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,488 shares of the companys stock after selling 2,092 shares during the quarter. Parametric Portfolio Associates LLCs holdings in Replimune Group were []

Equities research analysts expect Replimune Group, Inc. (NASDAQ:REPL) to announce earnings of ($0.58) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Replimune Groups earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.63). Replimune Group reported earnings of ($0.44) []

Replimune Group, Inc. (NASDAQ:REPL)s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $26.24 and last traded at $26.36, with a volume of 1495 shares changing hands. The stock had previously closed at $27.44. Several research firms have commented on REPL. SVB Leerink cut their price []

Emerald Advisers LLC increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 25.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 921,775 shares of the company’s stock after purchasing an additional 189,533 shares during the quarter. Emerald Advisers LLC’s holdings in Replimune Group […]

Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 35.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,016,937 shares of the companys stock after buying an additional 263,509 shares during the []

Cubist Systematic Strategies LLC lessened its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 96.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,215 shares of the companys stock after selling 32,115 shares during the period. Cubist Systematic Strategies LLCs holdings in Replimune Group were worth $47,000 as of its most recent SEC []

Credit Suisse AG cut its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 26.4% during the second quarter, HoldingsChannel reports. The fund owned 14,250 shares of the companys stock after selling 5,104 shares during the period. Credit Suisse AGs holdings in Replimune Group were worth $547,000 at the end of the most recent quarter. A number []

Piper Sandler started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Friday morning, PriceTargets.com reports. The brokerage issued an overweight rating and a $52.00 price objective on the stock. REPL has been the subject of several other reports. HC Wainwright restated a buy rating and set a $59.00 target price []

Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 2,441 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $33.50, for a total transaction of $81,773.50. The sale was disclosed in a filing with the SEC, which is accessible through []

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note issued to investors on Monday morning, Analyst Ratings Network reports. They currently have a $59.00 target price on the stock. REPL has been the subject of several other research reports. SVB Leerink lowered their price target on Replimune Group []

Replimune Group, Inc. has lost nearly all its share price gains since mid-October 2020 when it presented encouraging data on two of its oncolytic immunotherapy assets.

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today

Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma,

WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today a